Navigation Links
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:12/31/2007

FRAZER, Pa., Dec. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of TREANDA(R) (bendamustine HCl) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) who have progressed during or following treatment with rituximab or a rituximab-containing regimen. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment.

"TREANDA is the lead product in our oncology pipeline and with this second NDA submission for the product in 2007 we have achieved a significant milestone for our business," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "The clinical data supporting this submission highlight the potential of TREANDA to make a meaningful difference for patients with indolent NHL who have relapsed during or following treatment with rituximab."

The TREANDA NDA for relapsed indolent NHL is supported by three studies in patients with NHL, including one in combination with rituximab. In these studies, patients treated with TREANDA had a high rate of response and a manageable and tolerable side effect profile, with adverse events similar to those observed with other chemotherapy agents.

About TREANDA

TREANDA is a novel chemotherapeutic agent, a hybrid of a purine analog and an alkylator. Preclinical data demonstrate that TREANDA acts in two distinct ways to kill cancer cells. TREANDA damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death (non-apoptotic) pathway known as mitotic catastrophe (a disruption of no
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... will present at the Jefferies 2013 Global Healthcare Conference ... Hyatt New York. Richard Smith ... Hai Tran , Chief Financial Officer, will ... Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)...  Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., ... banking and therapeutics, announced today that StemCyte has become ... Indy car driven by James Jakes ... IndyCar 2013 season.   StemCyte, Inc. and Rahal ... of umbilical cord blood banking and its educational initiative ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... African-Americans in STEM industries, Black Data Processing Associates (BDPA), ... Day on June 8, 2013. This all-day event will ... arena, and learn the ins and outs from many ... to 3 p.m. at the New Jersey Institute of ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2
... to generate energy is a signifiant step closer following ... East Anglia (UEA). Published today by the leading ... Sciences (PNAS), the research demonstrates for the first ... enable bacterial cells to transfer electrical charge. The ...
... WASHINGTON, May 23, 2011The Annual Meeting of the American ... June 2, 2011, in New Orleans, Louisiana. Crystallography is ... in regular crystalline solids and in complicated molecules. The ... the structure of important materials are often calculated by ...
... (OTCQX: DATA), a technology and services company focused on ... announced the Company,s selection as a 2011 Crain,s Leading ... "Being once again recognized as an EDGE ... and its employees have to bringing a quality product ...
Cached Biology Technology:Discovery opens the door to electricity from microbes 2Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 2Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 3Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 4DATATRAK Recognized as 2011 Crain's Leading EDGE Award Winner 2
(Date:5/24/2013)... years, microRNAs (miRNAs) and other non-coding RNAs are ... specific proteins. In recent years they have emerged ... to establish tissue origin for cancers of unknown ... screen for disease, but clinically tractable, diagnostic methods ... not currently available. In this issue of the ...
(Date:5/23/2013)... , Automated conserved noncoding sequence ... evolution among grasses , Within the genome of ... that undergo little change in position and sequence over ... proteins. Some of these evolutionarily stable sequences, so-called conserved ... of other genes or the condensation of chromosomes, but ...
(Date:5/23/2013)... Investigators at Rollins School of Public Health at ... Institute of Technology, have received a $4 million ... Center at Emory University (Health and Exposome Research ... first exposome-based center grant awarded in the United ... by the National Institute of Environmental Health Sciences ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
... is a strong candidate for involvement in premenstrual dysphoric ... flux in hormones during the menstrual cycle. In a ... National Academy of Sciences , Rockefeller University researchers detail ... of the gene increases anxiety, dampens curiosity and tweaks ...
... has long been a model system for studying and understanding ... that cause influenza, measles and rabies. More ... be genetically modified to serve as an anti-cancer agent, exercising ... and as a potent vaccine against HIV. ...
... , REDWOOD CITY, Calif. ... leader in fingerprint identity and authentication solutions, continues to ... and franchise owners.  The latest version of the popular ... U.are.U® fingerprint biometrics technology from DigitalPersona, will be unveiled ...
Cached Biology News:Research identifies gene with likely role in premenstrual disorder 2Research identifies gene with likely role in premenstrual disorder 3Researchers reveal 3-D structure of bullet-shaped virus with potential to fight cancer, HIV 2Digital Dining Customers Demand Fingerprint Biometrics in Point-of-Sale Technology 2Digital Dining Customers Demand Fingerprint Biometrics in Point-of-Sale Technology 3
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
Biology Products: